Larvol Delta - BioVaxys-Reports-Positive-Clinical-Study-Results-from-Phase-1B2-PESCO-Trial-of-MVPS-with-Pembrolizumab-Keytruda-and-LowDose-Cyclophosphamide-for-Patients-with-Recurrent-Epithelial-Ovarian-Cancer-EOC

maveropepimut-S (MVP-S) - BioVaxys

Keytruda (pembrolizumab) - Merck (MSD)

https://www.newsfilecorp.com/release/280882/BioVaxys-Reports-Positive-Clinical-Study-Results-from-Phase-1B2-PESCO-Trial-of-MVPS-with-Pembrolizumab-Keytruda-TM-and-LowDose-Cyclophosphamide-for-Patients-with-Recurrent-Epithelial-Ovarian-Cancer-EOC

Jan 20, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next